TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.

Acute promyelocytic leukemia (APL) with WBC above 10 G/L has long been considered, even in the all-trans retinoic acid (ATRA) era, to carry a relatively poor prognosis (compared to  APL with WBC below 10 G/L), due to increased early mortality and relapse. However, early deaths can to a large extent...

Full description

Bibliographic Details
Main Authors: Charicleia Kelaidi, Lionel Ades, Pierre Fenaux
Format: Article
Language:English
Published: PAGEPress Publications 2011-09-01
Series:Mediterranean Journal of Hematology and Infectious Diseases
Subjects:
Online Access:http://www.mjhid.org/index.php/mjhid/article/view/298
id doaj-dbabb1d1d4c64ac292367850dedb136f
record_format Article
spelling doaj-dbabb1d1d4c64ac292367850dedb136f2020-11-24T23:57:32ZengPAGEPress PublicationsMediterranean Journal of Hematology and Infectious Diseases2035-30062011-09-0131e2011038e201103810.4084/mjhid.2011.038190TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.Charicleia Kelaidi0Lionel AdesPierre Fenaux1Department of Hematology, G. Papanikolaou Hospital of Thessaloniki, Exochi 57010, Greece.Service d’Hématologie, Hôpital Avicenne - Université Paris 13Acute promyelocytic leukemia (APL) with WBC above 10 G/L has long been considered, even in the all-trans retinoic acid (ATRA) era, to carry a relatively poor prognosis (compared to  APL with WBC below 10 G/L), due to increased early mortality and relapse. However, early deaths can to a large extent be avoided if specific measures are rapidly instigated, including prompt referral to a specialized center, immediate onset of ATRA and chemotherapy, treatment of coagulopathy with adequate platelet transfusional support, and prevention and management of differentiation syndrome. Strategies to reduce relapse rate include chemotherapy reinforcement with cytarabine and/or arsenic trioxide during consolidation, prolonged maintenance treatment, especially with ATRA and low dose chemotherapy, and possibly, although this is debated, intrathecal prophylaxis to prevent central nervous system relapse. By applying those measures, outcomes of patients with high risk APL have considerably improved, and have become in many studies almost similar to those of standard risk APL patients.http://www.mjhid.org/index.php/mjhid/article/view/298Leukemia, Promyelocytic Leukemia, Hyperleucocytosysis
collection DOAJ
language English
format Article
sources DOAJ
author Charicleia Kelaidi
Lionel Ades
Pierre Fenaux
spellingShingle Charicleia Kelaidi
Lionel Ades
Pierre Fenaux
TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.
Mediterranean Journal of Hematology and Infectious Diseases
Leukemia, Promyelocytic Leukemia, Hyperleucocytosysis
author_facet Charicleia Kelaidi
Lionel Ades
Pierre Fenaux
author_sort Charicleia Kelaidi
title TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.
title_short TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.
title_full TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.
title_fullStr TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.
title_full_unstemmed TREATMENT OF ACUTE PROMYELOCYTIC LEUKEMIA WITH HIGH WHITE CELL BLOOD COUNTS.
title_sort treatment of acute promyelocytic leukemia with high white cell blood counts.
publisher PAGEPress Publications
series Mediterranean Journal of Hematology and Infectious Diseases
issn 2035-3006
publishDate 2011-09-01
description Acute promyelocytic leukemia (APL) with WBC above 10 G/L has long been considered, even in the all-trans retinoic acid (ATRA) era, to carry a relatively poor prognosis (compared to  APL with WBC below 10 G/L), due to increased early mortality and relapse. However, early deaths can to a large extent be avoided if specific measures are rapidly instigated, including prompt referral to a specialized center, immediate onset of ATRA and chemotherapy, treatment of coagulopathy with adequate platelet transfusional support, and prevention and management of differentiation syndrome. Strategies to reduce relapse rate include chemotherapy reinforcement with cytarabine and/or arsenic trioxide during consolidation, prolonged maintenance treatment, especially with ATRA and low dose chemotherapy, and possibly, although this is debated, intrathecal prophylaxis to prevent central nervous system relapse. By applying those measures, outcomes of patients with high risk APL have considerably improved, and have become in many studies almost similar to those of standard risk APL patients.
topic Leukemia, Promyelocytic Leukemia, Hyperleucocytosysis
url http://www.mjhid.org/index.php/mjhid/article/view/298
work_keys_str_mv AT charicleiakelaidi treatmentofacutepromyelocyticleukemiawithhighwhitecellbloodcounts
AT lionelades treatmentofacutepromyelocyticleukemiawithhighwhitecellbloodcounts
AT pierrefenaux treatmentofacutepromyelocyticleukemiawithhighwhitecellbloodcounts
_version_ 1725453407969345536